Ernst & Young resigned as MiMedx's outside auditor after advising the company that the internal controls necessary for MiMedx to develop reliable financial statements do not exist.
News & Features
The company also released a weak outlook for 2019 and saw shares drop a little more than 17% as a result.
The partnership between Edwards Lifesciences and Bay Labs continues the trend of larger medtech firms teaming up with companies in the artificial intelligence space to enhance existing devices.
The medtech space was definitely piping hot with M&A activity earlier this year, but do firms still have that same thirst for deals going into 2019?
The robotic guidance and navigation system has already been used in surgeries in Greece, Germany, and Italy.
A recent breakthrough in the design of medical device cables is expected to enable a new generation of small, flexible, and intelligent catheters according to Japanese wire and cable supplier Junkosha.
The Marlborough, MA-based company said it could pick up a CE mark for the endoscopic ablation system sometime in mid-2019.
These companies have risen above the rest in 2018. Which one do you think deserves to wear the crown?
A team from Brigham and Women’s Hospital are developing a test that can detect tau protein, a calling card for Alzheimer’s disease.
By applying predictive analytics, medical device companies can make a shift to a proactive mode to avoid potential problems before they happen, according to an expert in business strategy and software engineering.
The technology was designed by Northwestern Medicine along with Northwestern’s McCormick School of Engineering scientists and has the potential to monitor, separately and accurately, UVB and UVA exposure for people at high risk for melanoma.
Medtronic agreed to pay a total of $50.9 million to resolve three separate claims against Covidien and ev3, both of which are now part of Medtronic.
The Menlo Park, CA-based company’s 50,000-patient trial will launch in 2019 and could be one of the most significant events of the year for the liquid biopsy market.
FDA proposed a new rule that, if finalized, could motivate more companies to choose the de novo pathway for new devices that do not have a modern predicate.